44.30
price up icon1.56%   0.68
after-market Handel nachbörslich: 44.46 0.16 +0.36%
loading
Schlusskurs vom Vortag:
$43.62
Offen:
$43.6
24-Stunden-Volumen:
3.07M
Relative Volume:
1.06
Marktkapitalisierung:
$11.60B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
25.03
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
+1.77%
1M Leistung:
+3.31%
6M Leistung:
+30.52%
1J Leistung:
+100.00%
1-Tages-Spanne:
Value
$43.45
$44.43
1-Wochen-Bereich:
Value
$42.66
$44.48
52-Wochen-Spanne:
Value
$21.82
$49.62

Exelixis Inc Stock (EXEL) Company Profile

Name
Firmenname
Exelixis Inc
Name
Telefon
(650) 837-7000
Name
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
Mitarbeiter
1,147
Name
Twitter
@exelixisinc
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
EXEL's Discussions on Twitter

Vergleichen Sie EXEL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
EXEL
Exelixis Inc
44.30 11.60B 2.17B 521.27M 633.79M 1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Herabstufung Wells Fargo Overweight → Equal Weight
2025-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2025-01-24 Herabstufung Oppenheimer Outperform → Perform
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-17 Herabstufung BofA Securities Buy → Neutral
2024-10-16 Bestätigt RBC Capital Mkts Outperform
2024-09-19 Eingeleitet UBS Neutral
2024-04-11 Herabstufung Barclays Overweight → Equal Weight
2023-12-19 Eingeleitet BTIG Research Buy
2023-12-15 Eingeleitet Citigroup Buy
2023-09-26 Eingeleitet H.C. Wainwright Buy
2023-08-22 Bestätigt Oppenheimer Outperform
2023-08-08 Eingeleitet SVB Securities Market Perform
2023-07-11 Fortgesetzt Morgan Stanley Equal-Weight
2023-05-10 Fortgesetzt Piper Sandler Overweight
2023-03-09 Eingeleitet Wells Fargo Overweight
2023-01-26 Eingeleitet Credit Suisse Outperform
2022-10-18 Eingeleitet JMP Securities Mkt Outperform
2022-06-24 Eingeleitet BMO Capital Markets Outperform
2021-11-19 Eingeleitet Piper Sandler Overweight
2021-11-03 Fortgesetzt Jefferies Buy
2021-10-07 Eingeleitet Jefferies Buy
2021-08-06 Bestätigt H.C. Wainwright Buy
2021-06-15 Eingeleitet H.C. Wainwright Buy
2021-05-18 Fortgesetzt Goldman Sell
2021-03-31 Eingeleitet Credit Suisse Outperform
2021-03-12 Eingeleitet Wolfe Research Outperform
2020-03-04 Eingeleitet Barclays Overweight
2020-01-13 Eingeleitet SunTrust Buy
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-03-18 Hochstufung Morgan Stanley Underweight → Equal-Weight
2018-09-17 Eingeleitet Goldman Neutral
2018-09-10 Eingeleitet Morgan Stanley Underweight
2018-05-11 Bestätigt Needham Buy
2017-10-17 Bestätigt Needham Buy
2017-10-17 Bestätigt RBC Capital Mkts Outperform
2017-10-16 Bestätigt SunTrust Buy
2017-09-22 Herabstufung Leerink Partners Outperform → Mkt Perform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-09-12 Bestätigt Needham Buy
2017-07-14 Eingeleitet SunTrust Buy
2017-03-31 Eingeleitet Needham Buy
2017-03-16 Eingeleitet Oppenheimer Perform
2017-02-28 Herabstufung Stifel Buy → Hold
2016-11-03 Eingeleitet Deutsche Bank Buy
2016-10-10 Hochstufung Piper Jaffray Neutral → Overweight
2016-09-15 Bestätigt Stifel Buy
Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

pulisher
Jun 18, 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance

Jun 18, 2025
pulisher
Jun 14, 2025

How to Take Advantage of moves in (EXEL) - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 14, 2025

Exelixis’s SWOT analysis: cabozantinib’s strength, zanzalintinib’s potential drive stock outlook - Investing.com Canada

Jun 14, 2025
pulisher
Jun 13, 2025

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis - Yahoo Finance

Jun 13, 2025
pulisher
Jun 12, 2025

EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL S - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis stock maintains buy rating at H.C. Wainwright on promising data - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis, Inc.'s (NASDAQ:EXEL) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st

Jun 12, 2025
pulisher
Jun 12, 2025

EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL S - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 10, 2025

Indexes Rise But Growth Plays Hit; Quanta Services, Exelixis, Google In Focus - Investor's Business Daily

Jun 10, 2025
pulisher
Jun 09, 2025

Kalkine: Exelixis Joins Momentum Wave Ahead of Russell 1000 Rebalance - Kalkine Media

Jun 09, 2025
pulisher
Jun 09, 2025

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance

Jun 09, 2025
pulisher
Jun 09, 2025

Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews

Jun 09, 2025
pulisher
Jun 09, 2025

Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLC - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Bank of America Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $38.94 - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Zacks Research Has Bullish Forecast for Exelixis Q2 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Exelixis Escapes Cancer Drug Invalidity Bid At PTAB - Law360

Jun 06, 2025
pulisher
Jun 06, 2025

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Analyst Expectations For Exelixis's Future - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Exelixis (EXEL) Sees Price Target Raised by B of A Securities | - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

BofA Adjusts Price Target for Exelixis (EXEL) Amid Critical Pipe - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (E - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exelixis at Jefferies Conference: Strategic Moves for Growth By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 07 - MarketScreener

Jun 04, 2025
pulisher
Jun 03, 2025

Exelixis Stock Surges 28% YTD: Should You Buy Now Or Sell? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel maintains hold rating on Exelixis stock, sets $38 target - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - MarketScreener

Jun 03, 2025
pulisher
Jun 02, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews

Jun 02, 2025
pulisher
May 31, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire

May 31, 2025
pulisher
May 30, 2025

2 Top Stocks to Buy With Less Than $100 - The Globe and Mail

May 30, 2025
pulisher
May 28, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

May 27, 2025
pulisher
May 26, 2025

Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Promising Growth Potential - DirectorsTalk Interviews

May 26, 2025
pulisher
May 25, 2025

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN

May 25, 2025
pulisher
May 25, 2025

Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa

May 25, 2025
pulisher
May 25, 2025

Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia

May 25, 2025
pulisher
May 25, 2025

Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

May 25, 2025

Finanzdaten der Exelixis Inc-Aktie (EXEL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Exelixis Inc-Aktie (EXEL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
WYSZOMIERSKI JACK L
Director
Jun 03 '25
Sale
43.09
7,535
324,683
358,882
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):